Introduction {#S1}
============

According to the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, version-5, Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by impairments in two domains: (1) communication and social interaction and (2) restricted, repetitive, and stereotyped patterns of behaviors and interests ([@B5]). According to Center for Disease Control and Prevention, 1 in 59 children is diagnosed with ASD. Approximately 30% of individuals with ASD also require psychological and psychiatric treatments for behavioral problems including hyperactivity, impulsivity, inattention, aggression, property destruction, self-injury, mood disorders, psychosis, and tic disorders ([@B54]; [@B18]). Symptoms of ASD usually begin in early childhood and are frequently accompanied by intellectual disability (75%), dysmorphic features and epilepsy (25%), and occasionally MRI and EEG abnormalities ([@B66]; [@B16]; [@B23]). However, since there are no definite biomarkers, the diagnosis is based on a standardized clinical assessment and relies basically on behaviors including speech delay and language deficits ([@B55]).

Several neuroimaging and genetic studies indicate dysregulation of serotonin in the pathogenesis of ASD. Serotonin is a neurotransmitter synthesized in the central nervous system (CNS) and plays a pivotal role in brain development. Dysregulation in serotonin is associated with aggression, anxiety, mood, impulsivity, sleep, ingestion behavior, and reward systems ([@B28]; [@B22]). Perhaps the most intriguing 5HT-related finding in ASD is hyperserotonemia, an increase of platelet 5-HT, which has been consistently observed in about one third of subjects with ASD ([@B3]; [@B28]; [@B68]; [@B48]). In addition, reduction in uptake of tryptophan (the precursor of 5-HT) and 5-HT synthesis, decreased 5-HT~2A~ receptor binding, and binding capacity of 5-HT transporter molecules (*SERT, 5-HTT*) have been detected in autistic brain using positron emission tomography and single-photon emission computed tomography ([@B24]; [@B20]; [@B56]; [@B43]; [@B76]).

Evidence showed the global 5-HT synthesis in frontal, temporal, and parietal cortex in children aged 2--5 years with ASD was significantly attenuated compare to neurotypical children which correlated with altered language development suggesting a disruption of serotonergic system in ASD brains during early childhood ([@B24]). As mentioned earlier, the serotonin transporter (*5-HTT*) involved in hyperserotonemia is encoded by *SLC6A4* gene, for which a causal link to ASD has been reported ([@B58]; [@B91]). The most extensively studied polymorphism associated with ASD is in the serotonin Transporter-linked polymorphic region (*5-HTTLPR*) located within the promoter region of the gene and presented with two alleles designated long (l) and short (s). Both modulate the expression and function of the serotonin transporter and they have been correlated with cerebral gray matter volume, hippocampal volume and amygdala response in ASD ([@B91]), aggression and ADHD in males ([@B19]).

In addition, case-control and family-based investigations with molecular approaches unveiled serotonin-associated candidate genes in ASD including tryptophan hydroxylase 2 (*TPH2*), Brain-Derived Neurotrophic Factor (*BDNF*) and Matrix metallopeptidase 9 (*MMP-9*) ([@B75]; [@B65]; [@B10]). *TPH2* is a gene located on chromosome 12 encoding for a rate-limiting enzyme for brain serotonin synthesis playing a role in ASD susceptibility associated phenotypic impairments and repetitive behavior ([@B29]; [@B63]; [@B97]). However, some studies have shown no significant correlation between *TPH2* variants and ASD ([@B81]; [@B84]).

*BDNF* has long been the focus of attention for underlying mechanisms leading to ASD. Several studies showed significant correlations between elevated *BDNF* levels in serum or blood and ASD ([@B67]; [@B74]; [@B30]; [@B82]; [@B98]). *BDNF* has a trophic effect for dopaminergic neurons both during brain development and maturity. It is involved in regulating neuronal survival, morphology, differentiation, synapse formation, and normal cognitive function. *BDNF* is trophic for CNS serotonin as well ([@B60]; [@B4]; [@B13], [@B14], [@B44]). A study in rodents has indicated that *BDNF* and serotonin react to the same environmental factors in reciprocal manner ([@B59]). For instance, heterozygous *BDNF* mice are extremely deprived of serotonin clearance in the CA3 region of hippocampus due to functional impairment of serotonin transporter rather than total amount of serotonin transporter ([@B33]). Notably, 5-HT and extracellular matrix (ECM) regulate learning and memory formation through morphological changes of dendritic spines during brain development ([@B88]; [@B37]).

*MMP-9*, one of various ECM modifiers, serves a pivotal role in long-term memory, synaptic plasticity, development of the CNS during synaptogenesis, as well as in neuro-inflammation, which are features consistently found in children with ASD ([@B83]; [@B94]; [@B38]; [@B49]). Intriguingly, amniotic fluid samples derived from 331 ASD individuals exhibited increased levels of *MMP-9* which may imply the neuroplastic disruption during prenatal period ([@B1]). Elevated *MMP-9* activation can also cause increased *BDNF* release and may contribute to the ASD phenotype, including autistic-like behavior and macrocephaly ([@B31]; [@B52]; [@B96]). Taken together, serotonin-associated genes including *TPH2*, *BDNF*, and *MMP-9* may be involved in the disruption of the serotonergic system and ultimately play a role in the pathology of ASD.

Selective serotonin reuptake inhibitors (SSRIs), which are widely prescribed and can influence peripheral and CNS 5-HT levels may correct dysregulation and alleviate ASD symptoms ([@B51]). The Food and Drug Administration has approved several SSRIs including citalopram, escitalopram, fluoxetine, fluvoxamine, and sertraline for treating psychiatric symptoms in ASD ([@B70]). However, a placebo-controlled study reporting the efficacy of sertraline in ASD patients has not been carried out. [@B86] reported the results of an open-label study of low dosed sertraline (25--50 mg daily) in nine children with ASD (6--12 years) and showed significant improvement in anxiety, irritability, and inflexibility. Later, [@B61] reported marked reduction of aggressive and repetitive behaviors in adult ASD patients.

Thus, evidence suggests that sertraline could be useful in young children with ASD since the serotonergic system is disrupted in early development of ASD children. Based on these findings, a 6-month randomized, placebo-controlled, double-blind clinical trial of low-dose sertraline in children ages 39--71 months old with ASD was conducted at the UC Davis MIND Institute to evaluate the efficacy and benefit with respect to early expressive and receptive language development and global clinical improvement ([@B79]). In the present study, we further investigated the participants to identify molecular biomarkers predictive of efficacy and responsiveness to sertraline treatment in ASD. Candidate genes were selected specifically on the basis of their role in serotonin metabolism, uptake and transport, including *TPH-2*, *5-HTTLPR*, *MMP-9*, and *BDNF*.

Materials and Methods {#S2}
=====================

Study Design {#S2.SS1}
------------

A 6-month randomized, placebo-controlled, double-blind clinical trial of sertraline treatment was conducted at the UC Davis MIND Institute. 179 subjects were screened for eligibility, and a total of 58 were randomized; 32 subjects to sertraline and 26 to placebo. Thirteen subjects, eight from the sertraline arm and five from the placebo arm, discontinued from the study. Forty five ASD subjects aged 39--71 months completed the sertraline clinical trial. However, for four subjects a blood sample was not obtained. Thus, biological specimens were collected for 41 subjects including eight females and 33 males. All patients were randomized and either received a placebo (*n* = 20) or sertraline (*n* = 21). This was the first exposure to sertraline for all the children. Sertraline was administered in liquid form in a dose of 2.5 mg per day in patients ages 2--3 years and 5.0 mg per day in those 4--6 years. The amount that was used at each 3 months visit was measured to document compliance. More details are described in [@B79]. Biological samples collected at baseline and post-treatment were approved by the UC Davis Institutional Review Board.

Clinical Measures {#S2.SS2}
-----------------

Clinical assessment of study participants involved primary outcome measures: Mullen Scales of Early Learning (MSEL) ([@B69]) expressive language raw score, expressive language standard score and Clinical Global Impression Scale-Improvement (CGI-I). The CGI-I score is a follow-up measure scored as follows: 1 = very much improved since the initiation of treatment; 2 = much improved; 3 = minimally improved; 4 = no change from baseline; 5 = minimally worse; 6 = much worse; 7 = very much worse since the initiation of treatment ([@B17]). Additionally, the following secondary outcome measures were used: MSEL subscales: fine motor, visual reception and receptive language score. For each participant, all assessments were completed both at baseline and at the 6-month follow up visit.

Molecular Measures {#S2.SS3}
------------------

Genomic DNA was isolated from 3 ml of peripheral blood following standard procedure (Qiagen, Valencia, CA) and used for genotype analysis. Plasma was collected using EDTA containing blood collection tubes: blood was centrifugated for 10 min at 1000 × *g* within 2 h of blood collection. Plasma was collected, aliquoted, and stored at −80°C.

*5-HTTLPR* was performed using 100--200 ng genomic DNA and 20 μM of the following specific primers, forward HTTP2A (5′-TGA ATG CCA GCA CCT AAC CC-3′), reverse HTTP2A (5′-TTC TGG TGC CAC CTA GAC GC-3′), following PCR conditions as detailed in [@B87]. *BDNF* (rs6265) and *TPH2* (rs4290270, rs7305115, rs11178997, and rs4570625) genotypes were determined using TaqMan SNP Genotyping Assay (Applied Biosystems) and the 7900HT Sequencer and Sequence Detection System Software (Applied Biosystems, Inc., Foster City, CA).

Plasma samples were collected from purple top EDTA containing collection tubes, to compare chemokines, *MMP-9* and *BDNF* levels before and after intervention. Furthermore, plasma samples from nine typically developing male controls (Age range: 4--18 years old) were used to compare their *BDNF* and *MMP-9* plasma levels to children with ASD, respectively.

To determine the *MMP-9* plasma activity, the Human MMP Magnetic Bead Panel 2 96-Well Plate Assay (Merck Millipore, Billerica, MA) was used. Preparation of plasma samples and reactions were performed according to the manufacturer's protocol.

*BDNF* plasma levels were measured using a Milliplex assay (EMD-Millipore-Bellerica/MA). Samples were diluted 100-fold with Assay Buffer. Overnight incubation was carried out for 17 h at 4°C with shaking. Samples were measured within 1 h of finishing protocol using Luminex bead reader.

Cytokine and Chemokine levels were measured using Milliplex MAP Human Cytokine and Chemokine Magnetic Bead Panel Immunoassay (EMD-Millipore-Bellerica/MA). It was a 10 plex kit which included beads specific for IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12(p70), IL-13, IFNg, TNFa. Plasma samples were prepared according to manufacturer's protocol and the plates were read on Bio-Plex 200 System (Bio-Rad).

Statistical Analysis {#S2.SS4}
--------------------

Mean subject age was compared between treatment groups using a two-sample *t*-test, and the proportions of male and female subjects were compared between treatment groups using Fisher's Exact Test.

The association between MSEL receptive and expressive language raw scores at baseline and molecular measures at baseline was analyzed using linear regression. The association between baseline CGI-S score and molecular measures at baseline was analyzed using proportional odds logistic regression ([@B2]). *P*-values were adjusted for multiple testing across molecular measures using the Benjamini-Hochberg false discovery rate controlling method ([@B12]).

The association between *BDNF* expression at baseline and *BDNF* genotype was analyzed using a one-way ANOVA model and Tukey HSD pairwise comparisons.

The changes in treatment group subjects in MSEL receptive language and expressive language scores were compared between genotypes using one-way ANOVA models and Tukey pairwise comparisons. CGI-I scores were compared between genotypes using proportional odds logistic regression.

Changes from baseline in molecular measures were compared between groups using one-way ANOVA models, with *P*-values adjusted across molecular measures using the Benjamin-Hochberg method.

The association between changes from baseline in MSEL receptive language and expressive language and changes from baseline in molecular measures were analyzed by group using linear models with effects for the molecular measure, treatment group, and their interaction. The association between CGI-I and changes from baseline in molecular measures was analyzed using proportional odds logistic regression models with effects for the molecular measure, treatment group, and their interaction.

Baseline expression of *BDNF* and *MMP-9* was compared between cases and controls using ANOVA models.

*BDNF* was log transformed prior to analysis for scaling purposes and to more closely satisfy ANOVA model assumptions. *MMP-9* was log transformed in the analysis in which it was used as a response (that comparing *MMP-9* between cases and controls) in order to more closely satisfy model assumptions.

Analyses were conducted using R, version 3.5.3 ([@B80]) Proportional odds logistic regression models were fitted using the R package ordinal, version 2019.2-9 ([@B21]).

Results {#S3}
=======

Study Subjects {#S3.SS1}
--------------

Biological samples were collected at baseline for 45 subjects (pre-treatment), among which 41 subjects had their follow up visits (post treatment). Forty one biological samples were used to compare the plasma levels of *MMP-9*, *BDNF* and selected cytokines. Among the 41 subjects, 20 were on placebo and 21 were treated with sertraline. The mean age at baseline for the placebo group was 51.9 months and that of the treatment group was 50.6 months ([Table 1](#T1){ref-type="table"}).

###### 

Subject Demographic Characteristics. Summary of age and gender by treatment group.

                                 Placebo         Treatment     All subjects   *P*-value
  ------------- ---------------- --------------- ------------- -------------- -----------
  *Age^a^ at*   N^c^             20              21            41             0.71
  *baseline*    Mean (SD)        51.9 (10.5)     50.6 (11.4)   51.2 (10.9)    
  *(months)*    Median (range)   54.5 (31--71)   54 (32--69)   54 (31--71)    
  *Gender*^b^   Female           4 (20%)         4 (19%)       8 (19.5%)      1
                Male             16 (80%)        17 (81%)      33 (80.5%)     

a

Age was compared between groups using a two-sample t-test.

b

Gender was compared between groups using Fisher's exact test.

c

N indicates the number of subjects.

Plasma samples derived from age and gender matched control children were utilized for measuring *BDNF* and *MMP-9* levels for comparison.

Molecular Measures {#S3.SS2}
------------------

Linear regression analyses of MSEL receptive language raw score at baseline by molecular measures at baseline showed that higher expression of IL-5 at baseline is associated with a significantly lower baseline MSEL receptive language raw score (*P* = 0.030), however, this result was no longer significant after multiple testing adjustment (adjusted *P* = 0.362).

An ANOVA model was used to compare *BDNF* expression level between children with ASD and controls. The results show that children with ASD had significantly higher *BDNF* expression levels compared to typical age matched children ([Figure 1A](#F1){ref-type="fig"}). However, sertraline did not normalize the *BDNF* levels in those treated with sertraline compared to the placebo group. Lower *MMP-9* expression levels were observed children with ASD than controls (*P* = 0.026) ([Figure 1B](#F1){ref-type="fig"}). No difference in *BDNF* and *MMP-9* expression were observed between the treatment and the placebo group at baseline.

![Boxplots showing significantly higher plasma *BDNF* levels **(A)** and lower *MMP-9* levels **(B)** in the ASD group compared to controls. The heavy line in each box represents the median, the lower and upper box edges represent the 25th and 75th percentiles, respectively, and the lower and upper whiskers represent the smallest and largest observations, respectively.](fgene-11-00308-g001){#F1}

When comparing the changes in MSEL expressive language raw score by *TPH2* (rs11178997) (A/T), we observed that subjects with the AT genotype had significantly higher MSEL expression language raw scores than subjects with the TT genotype (*P* = 0.031) ([Table 2](#T2){ref-type="table"}). Furthermore, after comparing the changes in MSEL expressive language raw scores by TPH2 (rs4290270), it was shown that subjects with the AA genotype had marginally significantly higher changes in MSEL expressive language raw scores compared to subjects with the TT genotype (0.049), with subjects with the AA genotype showing an increase in score and subjects with the TT genotype showing a decrease in score ([Table 2](#T2){ref-type="table"}).

###### 

MSEL Expressive Language Raw Score -- Change by TPH2 (rs11178997) (A/T) and TPH2 (rs4290270) (A/T) genotypes in the treatment group.

                          Genotype^a^        Mean (95% Confidence Interval)                      *P*-value^b^
  ----------------------- ------------------ --------------------------------------------------- ------------------
  **TPH2**                AT (*n*^c^ = 3)    16.00 (4.90, 27.10)                                 0.008
  **(rs11178997)**        TT (*n*^c^ = 12)   2.08 (−3.46, 7.63)                                  0.432
  **TPH2**                AA (*n*^c^ = 6)    12.0 (4.47, 19.53)                                  0.004
  **(rs4290270)**         AT (*n*^c^ = 8)    0.5 (−6.02, 7.02)                                   0.872
                          TT (*n*^c^ = 3)    −4.0 (−14.65, 6.65)                                 0.434
                                                                                                 
                          **Comparison**     **Difference in means (95% Confidence Interval)**   ***P*-value**^b^
                                                                                                 
  **TPH2 (rs11178997)**   AT -- TT           13.9 (1.51, 26.3)                                   0.031
  **TPH2**                AA -- AT           11.5 (−0.6593, 23.7)                                0.065
  **(rs4290270)**         AA -- TT           16.0 (0.0797, 31.9)                                 0.049
                          AT -- TT           4.5 (−10.7425, 19.7)                                0.725

a

Genotypes with fewer than three subjects with non-missing data were excluded.

b

P-values are adjusted for multiple pairwise comparisons using the Tukey HSD method.

c

N indicates the number of subjects.

ANOVA models were used to compare changes in molecular measures between treatment groups. The results showed that *BDNF* expression decreases significantly in both the treatment (*P* = 0.001) and placebo (*P* = 0.011) groups ([Figure 2](#F2){ref-type="fig"}). Although in the treatment group, IL-5 (*P* = 0.035) and IL-10 decreased significantly (*P* = 0.041), none of the changes were significant after multiple testing adjustment. No significant associations or changes between groups were observed for any of the other molecular markers.

![The graphs show a significant improvement for baseline to after treatment in the BDNF plasma level in both the sertraline and placebo groups. A line plot of log10 BDNF plasma levels by time point. Colored lines represent individual subjects and the heavy black lines show the group means.](fgene-11-00308-g002){#F2}

The results of linear models of change in MSEL receptive language raw score by changes in molecular measures in each group showed that there is a significant relationship between the pre-post change in MSEL receptive language raw score and change in several cytokines which were not statistically significant following adjustment for multiple testing.

Discussion {#S4}
==========

Selective serotonin reuptake inhibitors, including sertraline, inhibit the serotonin transporter which normally reuptakes serotonin into presynaptic serotonergic neurons, subsequently, increasing extracellular levels of serotonin ([@B15]). Sertraline has been approved to treat OCD in patients with ASD, based on the shared core symptoms of repetitive thoughts and behaviors in addition to the dysfunction of serotonergic system ([@B11]; [@B62]).

In this study we investigated the predictive efficacy of molecular biomarkers of sertraline, including *BDNF*, *MMP-9*, *TPH-2* and cytokines to determine whether sertraline normalizes the expression of any of these genes in young children with ASD.

*BDNF* is important for the regulation of neurodevelopment and neuroplasticity thus contributing to normal learning process and memory. Several studies demonstrated that *BDNF* levels in young children with ASD are higher than aged-match typical neurodevelopmental adults ([@B78]; [@B67]). Excess of *BDNF* and other neurotrophins may affect tissue volume ([@B27]; [@B92]). Taken together, elevated *BDNF* at early life may play an etiological role in ASD. This might be represented by the brain overgrowth as observed in many ASD children ([@B32]; [@B91]; [@B53]; [@B47]; [@B6]). Consistently with previous studies we found that *BDNF* levels were significantly higher in ASD compared to controls ([@B67]; [@B26]; [@B73]; [@B74]; [@B30]; [@B82]; [@B98]). However, these increased levels of *BDNF* were not normalized by sertraline. Specifically, our results show that the elevated *BDNF* levels in ASD are significantly larger than controls and sertraline can partially reduce the *BDNF* levels both in the treatment and placebo groups although there was no significantly difference after correction. As peripheral expression levels of *BDNF* in rats are associated with the level in CNS, we might imply that the concentration of peripheral *BDNF* can reflect the expression level in ASD brain as well ([@B50]; [@B39]). Accordingly, peripheral *BDNF* might be a potential biomarker for ASD ([@B99]).

Plasma *MMP-9* expression levels in ASD were significantly lower than controls which is contrary to the elevated *MMP-9* levels in amniotic fluid samples from 331 ASD cases suggesting fluctuation of *MMP-9* during early development in ASD ([@B1]). Despite different *MMP-9* expression levels, sertraline had no effect on *MMP-9*. *MMP-9* plays a pivotal role in neuronal survival, CNS development, synaptic plasticity, and neuroinflammation through triggering several neurotrophic factors including *BDNF* ([@B42]; [@B83]; [@B38]; [@B40]). Hence, it is plausible that *MMP-9* might contribute to the etiopathology of ASD as well. On the other hands, *MMP-9* can also mediate the inflammatory response through promoting proteolysis either by stimulating or suppressing inflammatory cytokines involved in ASD pathology ([@B95]; [@B77]; [@B36]). However, in our study, no significant differences were observed.

Extensive evidence has suggested the role of pro-inflammatory and anti-inflammatory cytokines involving the severity of problematic behaviors and developmental and adaptive malfunctions as seen in ASD ([@B7], [@B8], [@B72]). However, heterogeneity of immune function findings in ASD may imply that there is no definite type of inflammatory response responsible for the etiology of ASD ([@B64]).

The human *TPH2* is exclusively expressed in the brain, particularly in the serotonergic neurons of the dorsal and median raphe nuclei which is the primary source of serotonin ([@B90]; [@B9]; [@B100]). Accumulating evidence has proposed that several functional polymorphisms of *TPH2* gene are associated with psychiatric disorders including major depressive disorder (MDD), attention deficit hyperactivity disorder (ADHD), schizophrenia, and bipolar disorder ([@B34]; [@B35]; [@B85]; [@B25]; [@B45]; [@B41]).

The functional consequences of single nucleotide polymorphisms (SNPs) are not clear but could potentially modify the expression and the function of the *TPH2* gene. Candidate *TPH2* variants including the ones in our study have long been well replicated in case of MDD ([@B57]; [@B89]; [@B46]). Further, associations between *TPH2* polymorphisms and ASD susceptibility particularly repetitive and stereotyped behaviors suggesting that they might affect the ASD phenotypes and augment ASD susceptibility have been reported ([@B29]; [@B93]; [@B10]). However, in our treatment group the rs11178997 with AT genotype demonstrated significantly higher expression language raw scores than the TT genotype. Furthermore, variant rs4290270 with AA genotype showed slightly increased scores compared to TT genotype. Our findings suggest that sertraline might play a moderate role in expressive language in ASD depending on the *TPH2* genotype.

Conclusion {#S5}
==========

In conclusion, sertraline had no distinct effect on young children with ASD compared to placebo and on several biomarkers including in this trial albeit their potential from ample previous studies. Future investigations should be of longer duration and should include more ASD subjects, which is a limitation of this study, with less heterogeneity to gain more insights on how to improve the quality of life of children with ASD.
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